Latest Continuous Disclosure News

BPH Global has clarified the timing and rationale behind its disclosure of a binding Memorandum of Understanding with Indonesia’s National Research and Innovation Agency, confirming compliance with ASX rules.

Australian Vanadium Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information behind the market activity.

Finder Energy Holdings has clarified that its recent share price jump is driven by investor enthusiasm around key project milestones, dismissing any undisclosed information as a cause.

Betmakers Technology Group has addressed an ASX price query following a surge in its share price linked to media reports of potential M&A interest from Tabcorp. The company confirms compliance with continuous disclosure rules and has authorised its response through its board.

Manuka Resources has affirmed the material significance of a draft decision by New Zealand’s EPA declining consent for its Taranaki VTM Project, clarifying its disclosure timeline and compliance with ASX rules amid recent share price volatility.

Titanium Sands Limited has responded to ASX inquiries following a sharp share price drop and increased trading volume, confirming no undisclosed price-sensitive information. The company highlighted an unrelated Sri Lankan Supreme Court petition on illegal mining near its pending Mannar Island project.

Cyclopharm Limited has completed the initial phase of a $14 million share placement, issuing nearly 9.5 million shares at 95 cents each, with the remaining shares set for issuance later this month.

GreenX Metals has successfully completed a A$13.6 million placement while confirming Poland’s appeal against a Singapore court ruling, underscoring ongoing legal challenges alongside fresh capital.

EMC Gold has responded to an ASX price query following a sudden spike in its share price, confirming no undisclosed information exists and affirming compliance with continuous disclosure rules.

Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.

Electro Optic Systems (EOS) has firmly rejected allegations from a recent Grizzly Research report, highlighting its strengthened financial position, significant contract wins, and strategic acquisition to bolster its defence technology portfolio.

Wellnex Life Limited is exploring acquisition interest and convertible note funding to accelerate Pain Away's expansion and strengthen its financial footing, signaling a pivotal phase in its turnaround journey.